A phase 2 clinical study of IMFINZI (durvalumab) in combination with SNS-301 in patients with various locally advanced unresectable or metastatic/recurrent solid tumors
Latest Information Update: 14 May 2019
At a glance
- Drugs Durvalumab (Primary) ; SNS 301 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Sensei Biotherapeutics
- 14 May 2019 New trial record